Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Selcia, Cantab partner to target drug-resistant infections
October 2013
SHARING OPTIONS:

ESSEX, United Kingdom—A drug discovery collaboration was established in early September between Selcia and Cantab Anti-Infectives. The partners will seek to further Cantab's program for the development of advanced antibiotics against multidrug- resistant Gram-negative bacterial infections based on the polymyxin nucleus. Per the agreement, Selcia will provide medicinal chemistry resources to generate a variety of polymyxin-based entities to continue optimizing antibacterial activity against such strains in vitro and in vivo, as well as helping to optimize therapeutic index and provide a drug candidate that fits the target product profile.
 
"When we wanted to complement our internal medicinal chemistry efforts, we identified Selcia as our partner of choice for this project, as it has a highly successful track record working on complex medicinal chemistry projects and identifying development candidates from challenging starting points," said Cantab CEO Mike Dawson.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.